Interaction Checker

Interaksi Zanamivir

Zanamivir (Relenza), golongan antivirus, memiliki 20 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 0 mayor, 20 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi moderat (20)

  • AklidiniumantikolinergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • AminofilinmetilxantinModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Arformoterolagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • EpinefrinsimpatomimetikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Formoterolagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • IpratropiumantikolinergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Ipratropium dan salbutamolantikolinergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Isoprenalinagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Levosalbutamolagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Mirabegronagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Salbutamolagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Salmeterolagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • TeofilinmetilxantinModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Terbutalinagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • TiotropiumantikolinergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • UmeklidiniumantikolinergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Umeklidinium dan vilanterolantikolinergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

  • Vibegronagonis beta-adrenergikModerat

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (label Zanamivir, Peringatan dan perhatian)

Periksa Zanamivir terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.